tbuckley/cabot-search huggingface dataset:
Abstract 66: Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors
Authors: Elizabeth S. McKenna, Pablo Tamayo, Yoon-Jae Cho, E. Lorena Mora-Blanco, Courtney G. Sansam, Erik J. Tillman, Edward C. Koellhoffer, Scott L. Pomeroy, Charles W. M. Roberts
Journal: Cancer Research (2011)

Abstract SNF5 (SMARCB1/INI1/BAF47), a core subunit of SWI/SNF chromatin remodeling complexes, is a potent tumor suppressor that is specifically inactivated in a variety of aggressive pediatric cancers. We have recently demonstrated that SNF5 acts as a tumor suppressor not genetically via maintenance of genome integrity, but epigenetically via transcriptional regulation. However, few of the target genes essential for oncogenesis following SNF5 loss have been identified. Here, we demonstrate that aberrant epigenetic silencing of the tumor suppressor gene BIN1 is a conserved event in SNF5-deficient cancers and contributes to tumorigenesis. Comparative genomewide expression analysis reveals that BIN1 expression is strongly downregulated in SNF5-deficient malignant rhabdoid tumors (MRT) relative to other human tumors, and we also observe decreased Bin1 expression in murine Snf5-deficient lymphomas. The underlying mechanism is epigenetic silencing as reintroduction of SNF5 into deficient tumor cell lines results in increased SWI/SNF recruitment to the BIN1 promoter and increased BIN1 expression. Furthermore, expression of BIN1 specifically compromises the proliferation of SNF5-deficient MRT cell lines. BIN1 encodes a family of alternatively spliced adaptor proteins that have been implicated in cellular differentiation, tumor suppression, and immune escape of transformed cells, but its regulation has not been well characterized. Identification of BIN1 as a key SNF5 target reveals a novel mechanism by which epigenetically based changes can drive cancer formation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 66. doi:10.1158/1538-7445.AM2011-66
“Clip and let go” for resection of duodenal carcinoid: a new technique using the over-the-scope-clip
Authors: Juan Gutierrez, Shabnam Sarker, Mel Wilcox, Klaus Mönkemüller
Journal: Endoscopy (2014)

A 66-year-old man who had been found to have histologically-proven carcinoid located in the duodenal bulb distal to the pylorus ([Fig. 1 a]) was referred to our center for endoscopic resection. Endoscopic ultrasound (EUS) showed a 9-mm lesion extending into the submucosa but without invasion into the muscular layer. Endoscopic resection using both snare and ligation techniques failed ([Fig. 1 b]), so it was decided to remove the lesion using the over-the-scope clip (OTSC) system (Ovesco, Tübingen, Germany) [1]. The lesion was entrapped and suctioned into the channel and the OTSC was released ([Fig. 1 c]); however, resection of the lesion located above the clip failed. Therefore, we decided to leave the clip in situ and to repeat the endoscopy 2 weeks later.
Abstract 1388: Metastatic potential of B16 melanoma subclones indicated by cell stiffness measured by atomic force microscopy (AFM)
Authors: Masami Suganuma, Tatsuro Watanabe, Atsushi Takahashi, Hirota Fujiki
Journal: Cancer Research (2011)

Abstract To investigate a new parameter for measuring the metastatic potential of cancer cells, we conducted nanomechanical analysis using atomic force microscopy (AFM). AFM, a probe microscope, has the advantage of measuring cell stiffness (elasticity) in physiological conditions without any pretreatment. Since cancer cells are softer than normal cells, the cell stiffness measured by AFM can be utilized as a new cancer diagnostic marker. Experimentally, we examined whether cell stiffness might reflect the metastatic potential of cancer cells using three subclones (B16-F10, B16-BL6, and B16-F1) of B16 melanoma cells. Migration potential was first determined by Transwell assay: B16-F10 and B16-BL6 cells showed 3- and 2- times more migrated cells into reverse sides of filter, at 5 μg/ml concentrations of fibronectin, than did B16-F1 cells. This indicates that B16-F10, B16-BL6, and B16-F1 cells have metastatic potential in the order of high, intermediate, and poor, respectively. AFM measurement clearly shows significant differences in cell stiffness of three B16 subclones, while the morphology and growth rate of these subclones are almost the same. Median values of Young’ modulus with B16-F10, B16-BL6, and B16-F1 cells were 395.12 Pa, 771.13 Pa, and 868.45 Pa, respectively. The results showed that highly metastatic B16-F10 cells are least stiff, suggesting that cell stiffness (Young's modulus) is directly associated with metastatic potential. Furthermore, we found that treatment with green tea catechin EGCG increased the cell stiffness of B16-F10 cells to greater than that of non-treated cells, and it also inhibited of cell migration in Transwell assay. Moreover, an inactive catechin, EC, did not have any effect on cell stiffness or cell migration. The results with EGCG strongly support our previous finding that EGCG in drinking water inhibits the metastasis of B16-F10 cells into the lungs of C57/BL6 mice. We have present for the first time evidence that the cell stiffness, as determined by AFM, is a useful biomarker for predicting metastatic potential and developing new preventive agents against metastasis. We discuss the significance of this mechanical and biochemical property (cell stiffness) in metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1388. doi:10.1158/1538-7445.AM2011-1388
Adamantinomatous Craniopharyngioma Containing Teeth
Authors: Narlin Bennet Beaty, Edward Ahn
Journal: New England Journal of Medicine (2014)

A 4-month-old term male infant presented with increasing head circumference on routine pediatric visits. MRI of the brain revealed a heterogeneous, enhancing suprasellar mass (4.1 cm by 4.0 cm by 3.5 cm) on T1-weighted images.
SP0075 Swedish Case Study to Empower People with RMDs
Authors: B. Svanberg
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> The Swedish association of Reumatism educate fysioteraphists to hold so called patient school. How to live with a livelong illness and coping. The patient whit RMD will be empowered and in the long termed the patient is able to live richer and healthier life. <h3>Disclosure of Interest</h3> None Declared
P17.62 * THE IMPORTANCE OF DELAYED PSEUDOPROGRESSION AND THE PROBLEM WITH RANO IN GBM
Authors: E. A. Neuwelt, L. L. Muldoon, S. Gahramanov
Journal: Neuro-Oncology (2014)

Treatment of Glioblastoma Multiforme (GBM) with temozolomide (TMZ) plus radiotherapy [chemoradiotherapy (CRT)] can induce the inflammatory reaction known as pseudoprogression in a large proportion of patients. Pseudoprogression (Ps) is associated with increased survival; however, it is difficult to differentiate Ps from true tumor progression on conventional magnetic resonance imaging (MRI), and the time course, true incidence, and mechanisms to increase or decrease Ps are not known. This IRB-approved retrospective study determined the rate and timing of pseudoprogression and the survival of GBM patients who received adjuvant TMZ until tumor progression. METHODS: Patients with biopsy-proven newly diagnosed GBM at Oregon Health and Science University from January 2006 to June 2012 after standard CRT received adjuvant TMZ until tumor progression. Diagnosis of Ps was made using dynamic perfusion MRI with ferumoxytol (a nanoparticle blood pool agent) in comparison to RANO criteria. Patients received bevacizumab (Avastin) anti-VEGF monoclonal antibody upon tumor progression. RESULTS: In our single institutional experience with 68 consecutive patients, the overall median survival was 19.9 months. Perfusion MRI revealed Ps in 24 (35%) patients. Pseudoprogression developed in 12.5% of our patient population at time points beyond the arbitrary 3 month cutoff defined by the RANO criteria. Survival was significantly greater in patients with Ps than in patients without Ps, 34.7 months versus 13.4 months, respectively. The subgroup of patients with Ps and hypermethylated MGMT had longer survival than patients with Ps and nonhypermethylated MGMT: 54.1 versus 28.2 months respectively. The patients that never experienced Ps had poor survival despite receiving bevacizumab. DISCUSSION: Ps is associated with better outcome, especially if concurs with MGMT promoter methylation. This study emphasizes the importance of differentiating tumor progression and Ps for treatment decisions and survival prediction, and emphasizes that ferumoxytol perfusion MRI may help as a diagnostic tool. Our results compare favorably with the recent report of the AVAglio trial of bevacizumab in GBM. Ps was diagnosed in only 9.3% of patients within 1 month after CRT in the AVAglio trial. Usage of upfront bevacizumab in the AVAglio trial further decreased the rate of Ps to 2.2%. The decrease in the beneficial inflammatory effects of Ps may explain why patients treated with upfront bevacizumab show increased progression-free survival without an increased overall survival benefit. Altogether these results demonstrate a need to reevaluate the RANO criteria in GBM.
SAT0023 High Remission Rates in Patients with Early RA (ERA) in Usual Care
Authors: T. Rannio, J. Asikainen, P. Hannonen, T. Sokka
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Many randomized controlled trials (RCT:s) have shown excellent remission rates in ERA. However, the data concerning usual rheumatologic care of ERA is scarce and reported remission rates low. <h3>Objectives</h3> To describe remission rates and used medications in patients with ERA treated in a county hospital rheumatology outpatient clinic 2008-2011. <h3>Methods</h3> In the healthcare district of ca 280 000, all possible ERA-patients are referred to rheumatology clinic which applies the T2T principle, electronic monitoring of patients at each visit, and multidisciplinary care. Patients with new clinical diagnosis of ERA 2008-2011 were identified from the database including clinical characteristics and patient reported outcomes (PRO's). Clinical and treating variables between the groups were compared with non/parametric tests and Chi square test when applicable. <h3>Results</h3> In 2008-2011, 409 patients were clinically diagnosed as ERA, and among of 406 who had data for classification according to 2010 ACR/EULAR RA criteria, 310 were classified as RA, and 96 as undifferentiated arthritis (UA), respectively. Clinical and treatment comparisons are presented in Table. DAS28(ESR-3 variables) remission rates were at 3mo 58% vs 67% in UA vs.RA and at 12mo 79% vs 71% (p=n.s., Figure). <h3>Image/graph</h3> <h3>Conclusions</h3> Good clinical results are achievable in ERA and UA patients in usual care. <h3>References</h3> Ma MH, Scott IC, Kingsley GH, Scott DL Remission in early rheumatoid arthritis J Rheumatol 2010 Jul;37(7):1444-53 <h3>Disclosure of Interest</h3> None Declared
EARLY ATHEROPROTECTION THROUGH SYK INHIBITION FAILS IN ESTABLISHED DISEASE WHEN PLAQUE MACROPHAGES PROLIFERATE
Authors: Andreas Zirlik, Ingo Hilgendorf, Alexandra Lindau, Carmen Haerdtner, Nathaly Anto Michel, Bianca Dufner, Natalie Hoppe, Peter Libby, Christoph Bode
Journal: Journal of the American College of Cardiology (2016)
Robert Douglas Young
Authors: Helen Young
Journal: BMJ (2016)

Robert Douglas Young was born in Prestwich, Manchester, the younger son of William Allan Young. He moved to the London Borough of Wandsworth in later childhood, where his father was medical officer of health. Wartime student evacuations meant a move from his start in at Guy’s Hospital back to his family’s roots in Edinburgh, where his father and grandfather had both qualified.

He served in the Royal Naval Volunteer …
SAT0514 Does Hyperuricemia Worsen Pain and Function in Patients with Knee or Hip OA? Results from the Khoala Cohort
Authors: H.K. Ea, A.C. Rat, J. Sellam, S. Fellahi, J.-P. Bastard, L. Bernard, X. Chevalier, J. Capeau, F. Berenbaum, F. Guillemin, P. Richette
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Several reports have found an association between gout and osteoarthritis (OA). Urate levels in OA synovial fluid has been shown to associate with both knee OA severity and production of proinflammatory cytokines. However, the impact of serum urate (SUA) levels on pain and disability or radiographic damages in patients with established knee or hip OA remains unknown <h3>Objectives</h3> To search for an association between SUA levels and OA severity and OA symptoms in a cross-sectional analysis of a large cohort of patients <h3>Methods</h3> Data are from 863 subjects with knee or hip OA from the KHOALA (Knee and Hip Osteo-Arthritis Long-Term Assessment) cohort. For each patient, SUA, CRPus, serum adipokines and lipids levels were assessed at inclusion. Baseline clinical data included the WOMAC (total, pain, stiffness and function) and the Harris, the IKS and Osteoarthritis Knee and Hip Quality of Life (<i>OAKHQOL</i>) scores. Associations between SUA levels and OA symptoms and disability was searched using uni and multivariate linear regression and associations between SUA levels and the presence of one or more radiographic OA with multivariate logistic regression. <h3>Results</h3> 863 patients (69.1% women) were included. Mean age was 61.9 (±8.5) years and mean BMI 29.4 (±6) kg/m<sup>2</sup> . 87 (10.1%) patients had diabetes. OA involved uni- or bilateral knees in 653 patients and uni- or bilateral hip in 286 patients. Mean SUA levels was 340 μmol/l (range 110.0-910.0). Hyperuricemia (SUA &gt;360 μmol/l) was observed in 305 (35.3%) patients. The level of uricemia was weakly correlated with BMI (r=0.23), insulinemia (r=0.273) and the triglycerides level (r=0.296). SUA levels did not significantly correlate with the WOMAC, the Harris, the IKS or the <i>OAKHQOL</i> scores in patients with either symptomatic knee or hip OA. In addition, SUA was not associated with the number of symptomatic knee or hip OA joints or radiographic knee or hip OA joints <h3>Conclusions</h3> In this large cohort of patients with knee or hip OA, SUA levels were not associated with OA symptoms, severity or radiographic damages. Such results do not exclude a prognostic value of SUA on OA progression. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3864
“Phytamins” Are Not Ready for Public Consumption
Authors: Peggy Eastman
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article “Phytamins” Are Not Ready for Public Consumption Get access Peggy Eastman Peggy Eastman Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 19, 4 October 1995, Pages 1430–1432, https://doi.org/10.1093/jnci/87.19.1430 Published: 04 October 1995
Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Authors: L Pusztai, J Jeong, Y Gong, JS Ross, C Kim, GN Hortobagyi, S Paik, WF Symmans
Journal: Cancer Research (2009)

Abstract Abstract #54 Objective: We assessed Tau protein expression in patients who participated in the National Surgical Breast and Bowel Project (NSABP)-B28 clinical trial using immunohistochemistry. Expression levels were correlated with disease-free (DFS) and overall survival (OS) and we also examined if there is interaction between this marker and paclitaxel efficacy. Patients and Methods: Tissue microarrays were available for 1942 patients (63 % of all trial participants) who were included in the NSABP-B28 clinical trial and were randomized to receive either 4 courses of doxorubicin/cyclophosphamide (AC) or AC followed by 4 additional courses of paclitaxel (ACT) adjuvant chemotherapy. All patients with hormone receptor positive tumors also received adjuvant endocrine treatment. Immunohistochemistry for Tau was performed at MD Anderson Cancer Center blinded to clinical outcome. Correlation with survival was performed by the NSABP Statistical Center. Results: Forty-three percent of tumors were Tau-positive defined as equal or greateer staining than in normal breast epithelium. Tau expression correlated strongly with estrogen receptor (ER)-positive status (p&amp;lt;0.0001). In univariate analyses, Tau, ER and HER-2 expression as well as grade, tumor size and nodal status were each independently and significantly associated with DFS and OS (p&amp;lt;0.003). In multivariate analysis, the same variables except HER2 remained significant. However, there was no significant interaction between Tau expression and benefit from paclitaxel in the entire population or among the ER-positive or ER-negative subsets, respectively. Conclusion: High Tau protein expression is associated with better prognosis including longer disease-free and overall survival in patients treated with adjuvant anthracyline and paclitaxel chemotherapy and endocrine therapy. However, we could not detect a statistically significant interaction between Tau expression and paclitaxel benefit. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 54.
THU0390 Effect of Glucocorticoid Treatment on Wnt Signalling Antagonists (Sclerostin and Dkk-1) and their Relationship to Bone Turnover and Bone Mass
Authors: L. Gifre, P. Peris, S. Ruiz-Gaspà, A. Monegal, B. Nomdedeu, N. Guañabens
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Wnt-ß-catenin signalling and its antagonists (sclerostin and Dkk-1) play an important role in the regulation of bone mass and osteoblastogenesis. Glucocorticoid therapy (GCCT) is a well known factor related to decreased bone formation and osteoporosis development. <h3>Objectives</h3> To analyze the effect of GCCT on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship to bone mass and bone turnover. <h3>Methods</h3> 22 patients (11M/11F, aged 48±20 yrs) recently initiating GCCT were prospectively included (≥7.5mg/day, ≤6months), excluding patients with associated metabolic bone diseases or on antiosteoporotic treatment. Bone turnover markers (Bone formation: P1NP, bone AP; Bone resorption: sCTx), Wnt antagonists (serum sclerostin and Dkk-1, determined by ELISA, Biomedica Gruppe, Austria) were assessed in all patients (at baseline and 12 months). Bone mineral density (BMD) was performed to assess osteoporosis. The results were compared with 20 healthy controls. <h3>Results</h3> The mean daily GCCT dose was 66±16 mg/day. Idiopathic thrombocytopenic purpura (73%) and hemolytic anemia (14%) were the most frequently associated conditions. Patients on GCCT showed a significant decrease in bone formation markers versus controls (PINP: 19.6±9.4 vs. 44.1±8.9 ng/ml, p=0.001) and increased bone resorption (sCTx: 0.58±0.23 vs. 0.4±0.17 ng/mL, p=0.049). Patients on GCCT had decreased Dkk-1 compared to controls (31.8±28.1 vs. 46.8±15.3 pmol/L, p=0.028) with similar sclerostin values (39.7±21.3 vs. 32.9±19.3 pmol/L, p=0.399). 20% had densitometric osteoporosis. Sclerostin correlated positively with GCCT doses (r=0.505, p=0.016) and lumbar BMD (r=0.554, p=0.008), and negatively with bone AP (r=-0.510, p=0.015). At 12 months, Dkk-1 significantly decreased compared to baseline (16.6±13.8, p=0.02), and sclerostin tended to increase (49.2±12.0, p=0.496). <h3>Conclusions</h3> The effect of GCCT on the serum levels of the Wnt signalling parameters differs depending on the antagonist evaluated. Dkk-1 levels decreased after the initiation of GCCT whereas sclerostin values tended to increase and showed a relationship to the dose of GCC and bone formation parameters. <h3>Acknowledgements</h3> Work funded by a grant from Societat Catalana de Reumatologia. <h3>Disclosure of Interest</h3> None Declared
1148 AGE, FIBROSIS AND DIABETIC STATUS, BUT NOT ETHNICITY, INFLUENCES THERAPEUTIC RESPONSE IN GREEK AND EGYPTIAN TREATMENT-NAIVE PATIENTS INFECTED WITH HEPATITIS C GENOTYPE 4
Authors: V. Papastergiou, D. Dimitroulopoulos, L. Skorda, P. Lisgos, I. Ketikoglou, N. Kostas, S. Karatapanis
Journal: Journal of Hepatology (2012)
AB0939 Canakinumab in Clinical Practice. Effectiveness in A Cryopyrin-Associated Periodic Syndrome Single Center Cohort:
Authors: V. Moreira Navarrete, F.J. Toyos Saenz de Miera, C. Vargas Lebron, F. Navarro Sarabia
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Cryopyrin-associated periodic syndrome (CAPS) comprises a group of rare, but severe, autoinflammatory diseases, characterized by urticaria, periodic fever, central nervous system inflammation, arthropathy, and increased risk of amyloidosis. In a recent trial the use of subcutaneous doses of 150 mg of canakinumab every 8 weeks was associated with complete control of clinical manifestations and laboratory parameters in patients with CAPS. <h3>Objectives</h3> The aim of this study was to verify efficacy and safety of the drug in clinical practice. <h3>Methods</h3> Retrospective longitudinal observational study, which included all patients diagnosed with CAPS in a tertiary hospital. Demographic and disease characteristics of all patients were collected. The decision to treat was performed by their rheumatologists. Clinical and laboratory variables at last follow-up were compared with those registered at Canakinumab treatment baseline. Percentages were obtained for qualitative variables and means with standard deviation (SD) for quantitative variables. Comparison between disease activity before and after therapy was performed with a t -student test. <h3>Results</h3> 10 genetically proved CAPS patients were included. 9 of them presented with the typical MWS phenotype and one of them patients with an overlapping MWS/FCAS phenotype. Seven of the patients belonged to the same family. All 10 patients were heterozygous carriers of different mutations in the NLRP3 gene: p.Thr-348-Met in exon 3, D303N in all family affected members, a deletion of bp (A) in exon 3, a mutation not described before, and finally, pR260W. Because disease activity, 50% of the patients were treated with a subcutaneous dose of 150 mg every 8 weeks of Canakinumab. Clinical and laboratory parameters of those patients are shown in Table 1. Both clinical and laboratory parameters responded quickly to that therapy. The mean decrease in CRP levels was 83.2 mg/L (SD 64.1) (p 0.04) in the levels of ESR of 40.8 mm/h (SD 24.9) (p 0,02). The mean increase in hemoglobin levels was 2.5 points (SD 2.62) (p 0.1) and the mean decrease in the platelet count was 161250 (SD 158838) (p 0.135). One of the patients is in a reduced dose schedule, receiving canakinumab every 10 weeks. No patients presented with any adverse events during follow up. <h3>Conclusions</h3> The use of canakinumab in daily practice is associated with persistent satisfactory control of disease activity. Here 10 patients with different mutations are presented, including a not previously reported mutation. <h3>References</h3> Muckle TJ, et al. QJM 1962;31:235-48. Calvo I, et al. Med Clin (Barc) 2011;136(Supl 1):16-21. Houten SM, et al. Cell Mol Life Sci 2003;60:1118-34. Lachmann HJ, et al. N Engl J Med2009 Jun;360(23):2416-25 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5712
Determining the Prevalence of EGFR Mutations in Asian and Russian Patients (PTS) with Advanced Non-Small-Cell Lung Cancer (ANSCLC) of Adenocarcinoma (ADC) and Non-Adc Histology: Ignite Study
Authors: B. Han, S. Tjulandin, K. Hagiwara, N. Normanno, L. Wulandari, L. Konstantin Konstantinovich, A. Hudoyo, M. Ratcliffe, R. McCormack, M. Reck
Journal: Annals of Oncology (2015)